A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

Trial Profile

A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Givinostat (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Italfarmaco
  • Most Recent Events

    • 05 Dec 2017 According to an Italfarmaco media release, data from the study will be presented at the 59th American Society of Hematology (ASH) Meeting & Exposition.
    • 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top